We are live on
!
Find out more
AbCellera Biologics
ABCL
ABCL
138 hedge funds and large institutions have $552M invested in AbCellera Biologics in 2023 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 38 reducing their positions, and 51 closing their positions.
New
Increased
Maintained
Reduced
Closed
204% more call options, than puts
Call options by funds: $6.1M | Put options by funds: $2.01M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 38
1.73% less ownership
Funds ownership: 43.21% → 41.48% (-1.7%)
19% less funds holding
Funds holding: 170 → 138 (-32)
32% less capital invested
Capital invested by funds: $809M → $552M (-$257M)
63% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 51
Holders
138
Holders Change
-32
Holders Change %
-18.82%
% of All Funds
2.19%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
19
Increased
38
Reduced
38
Closed
51
Calls
$6.1M
Puts
$2.01M
Net Calls
+$4.09M
Net Calls Change
-$743K
Top Buyers
Top Sellers
| 1 |
Millennium Management
New York
|
-$10.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$8.78M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$7.33M |
| 4 |
Renaissance Technologies
New York
|
-$5.14M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$3.98M |
